Dr. Dinesh Kumar Sarwal, Senior Director (IPR), Jubilant Pharmova Ltd.
Overview: Chief IPR Strategist with key role in managing and facilitating nurture Innovation culture, Ideation, designing, IP protection, IP compliance and support on commercialization of product and technologies of business interest. Work experience in R&D departments of pharmaceutical companies like Sun Pharma Advanced Research Centre (SPARC), Panacea Biotech Ltd and Ranbaxy Research Lab and presently spearheads IPR department of Jubilant Pharmova and Jubilant Radiopharma
Pharmaceutical Technologies: NCE, API, Intermediates, Generics (Solid Oral, Liquid, NDDS, Drug Device, Opthalmic, Injectable, Drug Device), Biologicals (Peptide, Allergenic extract), Veterinary Dosage, Medical Devices and Artificial Intelligence (AI) technologies
Para IV ANDA: 50+ successful Para IV USA ANDA filings (including FTF)
Patent Opposition: Successful track record in USA (successful Inter Partes Review Patent opposition), EU (Successful Post-Grant Opposition), India (Post-Grant Patent opposition), and PCT 3rd party observations
Patent Litigation Management: Favorable court decisions in USA (District Court, CAFC and International Trade Commission), Europe, Canada, Australia and other ROW markets
IP Award for Organization: Successfully led Jubilant Pharmova IPR team and secured 2023 CII Special National IPR Award under Life Sciences Category (Due to IP compliance policies and IP based commercial technologies)
Individual and Team Awards: winner of prestigious 20+ Jubilant Pharmova Chairmen awards on Leadership and successful R&D projects (Change Master of Year, Extramiler of the Year, Tranzformer of the Year, Pioneer of the Year)
Patent Publications (Inventor): 10+ (including granted USA Patents on USFDA approved dosage forms like Solid Oral, Injectable and Radiopharmaceutical technologies and products)
Research Publications: 170+ (Research papers and Book Chapter) in international Journal of repute on innovative pharma products and technologies
IPR Publications: 1. Co-author of CII white Paper on “IPR Issues with Respect to Pharmaceutical Sector-2023” and 2. Co-author of Book chapters published in “CII Book on IP FOR START-UPs AND MSMEs-2023”
IPR and Pharma Technology Policy Expert: 1. Member of CII National Committee on Intellectual Property Rights (FY: 2015-FY 2025) 2. Member of CII Expert Group (2023) to develop a scale on Technology Readiness Levels (TRL) 3. Member CII National Task Force on Genomics (2023)
G20/B20 Technology, Innovation, R&D Task Force Member (2023): 1. Member of B20 task force 2023 (under the ambit of G20, held in India) on Technology, Innovation, R&D 2. Co-lead International and national Pharma and life Sciences companies representative consortium and drafted a white paper on Technology, Innovation, R&D sub-group on Cancer detection and Cure techniques
Education: Pharm, M. Pharm., Ph.D, from University Institute Pharmaceutical Sciences (UIPS), Panjab University, Chandigarh
- Recipient of open fellowship from UGC and CSIR during doctoral research work at Panjab University
- Registered Indian Patent Agent (IN/PA 5535)
- Certificate course on IPR Valuation